Fig. 2
From: Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
Correlation between molecular characteristics of the cell lines and synergism of the niraparib-SN38 combination. The distribution of the combination indexes (CIs) at ED50, ED75 and ED90 between MSS and MSI cell lines is not significantly different (a). No significant difference is also observed across consensus molecular subtypes (CMSs) (b). Cell lines carrying non-synonymous mutations in BRCA2 (BRCA2 mut) do not show a lower CI to the combination of niraparib and SN38 compared to BRCA2 wild type (wt) (c). On the other hand, cell lines carrying a non-synonymous or truncating mutation in ATM gene (ATM mut) present a significantly lower CI values with respect to ATM wild type (ATM wt) cell lines (d). *: p < 0.05; **: p < 0.01